BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 34301811)

  • 1. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
    Kirtane K; Elmariah H; Chung CH; Abate-Daga D
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
    Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
    Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular therapy for the treatment of solid tumors.
    Grimes JM; Carvajal RD; Muranski P
    Transfus Apher Sci; 2021 Feb; 60(1):103056. PubMed ID: 33478888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
    Tesfaye M; Savoldo B
    Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive cellular therapies: the current landscape.
    Rohaan MW; Wilgenhof S; Haanen JBAG
    Virchows Arch; 2019 Apr; 474(4):449-461. PubMed ID: 30470934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Therapy in NSCLC: Between Myth and Reality.
    Imbimbo M; Wetterwald L; Friedlaender A; Parikh K; Addeo A
    Curr Oncol Rep; 2023 Oct; 25(10):1161-1174. PubMed ID: 37646900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.
    Hübbe ML; Jæhger DE; Andresen TL; Andersen MH
    Front Immunol; 2020; 11():578349. PubMed ID: 33101304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
    Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
    Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
    Front Immunol; 2021; 12():725330. PubMed ID: 34386017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges.
    McGowan E; Lin Q; Ma G; Yin H; Chen S; Lin Y
    Biomed Pharmacother; 2020 Jan; 121():109625. PubMed ID: 31733578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
    Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
    Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T cell therapy: Boosting the immune system to fight cancer.
    Leon E; Ranganathan R; Savoldo B
    Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.